Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer.
Epithelial ovarian cancer
PTEN
TRPV1
tumor marker
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
09
02
2020
revised:
22
02
2020
accepted:
06
03
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
24
11
2020
Statut:
ppublish
Résumé
Transient receptor potential vanilloid type 1 (TRPV1) has been studied in human malignancies, but has not been studied in epithelial ovarian cancer (EOC). We, therefore, investigated the significance of TRPV1 and correlation with phosphatase and tension homolog (PTEN) in EOC. Immunohistochemical analyses for TRPV1 and PTEN were performed using a tissue microarray. Moreover, the role of TRPV1 in cell growth was assessed in a EOC cell line. High TRPV1 expression and the combination of high TRPV1 and low PTEN expression were an independent prognostic factor for overall survival and disease-free survival. In vitro results demonstrated that knockdown of TRPV1 was associated with decreased cell viability and colony formation. There is a strong association between TRPV1 and PTEN and the combination of TRPV1 and PTEN is a strong indicator of prognostic predictor in EOC.
Sections du résumé
BACKGROUND
BACKGROUND
Transient receptor potential vanilloid type 1 (TRPV1) has been studied in human malignancies, but has not been studied in epithelial ovarian cancer (EOC). We, therefore, investigated the significance of TRPV1 and correlation with phosphatase and tension homolog (PTEN) in EOC.
MATERIALS AND METHODS
METHODS
Immunohistochemical analyses for TRPV1 and PTEN were performed using a tissue microarray. Moreover, the role of TRPV1 in cell growth was assessed in a EOC cell line.
RESULTS
RESULTS
High TRPV1 expression and the combination of high TRPV1 and low PTEN expression were an independent prognostic factor for overall survival and disease-free survival. In vitro results demonstrated that knockdown of TRPV1 was associated with decreased cell viability and colony formation.
CONCLUSION
CONCLUSIONS
There is a strong association between TRPV1 and PTEN and the combination of TRPV1 and PTEN is a strong indicator of prognostic predictor in EOC.
Identifiants
pubmed: 32345672
pii: 17/3/309
doi: 10.21873/cgp.20191
pmc: PMC7259890
doi:
Substances chimiques
Biomarkers, Tumor
0
TRPV Cation Channels
0
TRPV1 protein, human
0
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-319Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Breast Cancer (Dove Med Press). 2016 Dec 13;8:243-252
pubmed: 28008282
Int J Mol Med. 2018 Mar;41(3):1724-1730
pubmed: 29286076
Eur Urol. 2005 Oct;48(4):691-8
pubmed: 15992990
J Clin Invest. 2014 Sep;124(9):3793-806
pubmed: 25083990
Ann Oncol. 2017 Nov 1;28(suppl_8):viii61-viii65
pubmed: 29232466
DNA Cell Biol. 2017 Nov;36(11):976-982
pubmed: 28872922
J Neurochem. 2007 Aug;102(3):977-90
pubmed: 17442041
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):325-32
pubmed: 18034335
Cell Death Dis. 2019 Jun 12;10(6):460
pubmed: 31189890
Cancer Discov. 2012 Jan;2(1):56-67
pubmed: 22328975
Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):83-90
pubmed: 26708603
Antioxid Redox Signal. 2007 Dec;9(12):2087-98
pubmed: 17979524
Cancer Genet Cytogenet. 2008 Oct;186(1):25-32
pubmed: 18786439
Nat Immunol. 2014 Nov;15(11):1055-1063
pubmed: 25282159
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Cancer Manag Res. 2018 Jun 22;10:1647-1655
pubmed: 29970964
J Clin Diagn Res. 2012 Nov;6(9):1495-8
pubmed: 23285439
J Clin Endocrinol Metab. 2014 Sep;99(9):E1738-43
pubmed: 25029427
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
Anticancer Res. 2016 Nov;36(11):5765-5771
pubmed: 27793898
Free Radic Biol Med. 2012 Nov 15;53(10):1977-87
pubmed: 22922338
Biochim Biophys Acta. 2009 Jun;1793(6):953-8
pubmed: 19103233
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
Anticancer Res. 2014 Mar;34(3):1387-400
pubmed: 24596386
J Cancer Res Clin Oncol. 2009 Apr;135(4):507-14
pubmed: 18830626
Anticancer Res. 2016 Mar;36(3):837-43
pubmed: 26976969
Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S53-67
pubmed: 10396301
Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29
pubmed: 12838335
Cancer Res. 2012 Jun 1;72(11):2701-4
pubmed: 22593197
J Enzyme Inhib Med Chem. 2013 Jun;28(3):539-44
pubmed: 22299584
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
BMC Cancer. 2014 Dec 07;14:921
pubmed: 25481381
J Invest Dermatol. 2018 Oct;138(10):2205-2215
pubmed: 29580868
Am J Obstet Gynecol. 2003 Dec;189(6):1660-5
pubmed: 14710094